Attendee Registration - 6:30 am to 6:00 pm
EXHIBITIONS OPEN 11:30 Am to 4:30 pm
Thursday, September 12, 2019 |
||
Plenary Session |
Faculty |
Scheduled Time |
| Welcome to IMW17 | S Treon (Chair) P. Richardson (Co-Chair) | 8:00 AM |
| Keynote Address | Hon. Martin Walsh, Mayor of Boston (Introduction by S. Treon) |
8:20 AM |
| History of IMW | R Kyle (Introduction by Ken Anderson) |
8:30 AM |
| IMS President Address: State of the Art for Myeloma in 2019 | J San Miguel (Introduction by N Munshi) |
8:40 AM |
| Precursor Conditions | ||
| Session Chairs | R Kyle / F Davies | |
| Monoclonal Gammopathy of Unknown Significance | R Kyle | 8:55 AM |
| Risk factors for MGUS/SMM progression | V Rajkumar | 9:00 AM |
| Genomic Profiling: How is MGUS/SM different from Active MM? | N Bolli | 9:15 AM |
| Role of the Microenvironment in MGUS progression | M Dhodapkar | 9:30 AM |
| MGRS and other Paraprotein Related Conditions | J Fermand | 9:45 AM |
| Management of Smoldering Myeloma | M Mateos | 10:00 AM |
| New Concepts in Preventing SM Progression | I Ghobrial | 10:15 AM |
| Multiple Myeloma: Diagnosis and Management | ||
| Session Chairs | M Boccadoro/V Rajkumar | 10:30 AM |
| Diagnostic Criteria and Workup in 2019 | S Kumar | 10:30 AM |
| How do we use prognostic factors to Guide Treatment Decisions? | P Sonneveld | 10:45 AM |
| When and how should MRD be evaluated in MM? | B Paiva | 11:00 AM |
| Should MRD status guide drug development and approval? | F Gay | 11:15 AM |
| Challenges with current MM response criteria | J Blade | 11:30 AM |
| Imaging Approaches for MM | E Zamagni | 11:45 AM |
Lunch and EXHIBITionS 12:00 to 1:00 pm |
||
| Multiple Myeloma Genomics | ||
| Session Chairs | R Fonseca/W Chng | |
| Somatic Variants in Newly Diagnosed MM | H Avet-Loiseau | 1:00 PM |
| Clonal Diversity and Evolution in Myeloma | N Munshi | 1:15 PM |
| Transcriptome of Malignant Plasma Cells | G Morgan | 1:30 PM |
| Epigenomics of Myeloma | C Ott | 1:45 PM |
| Signalomics of Malignant Plasma Cells | M Raab | 2:00 PM |
| Importance of Microbiome in MM Growth and Survival | L Bergsagel | 2:15 PM |
| Multiple Myeloma: Current Treatment Approaches | ||
| Session Chairs | P Richardson/M Mateos | |
| Treatment of Newly Diagnosed Myeloma Transplant Eligible | M Cavo | 2:30 PM |
| Treatment of Newly Diagnosed Myeloma Non-Transplant | T Facon | 2:45 PM |
| Consolidation Strategies for MM | E Staudtmauer | 3:00 PM |
| Maintenance Strategies for MM | P McCarthy | 3:15 PM |
| Treatment Options for Relapsed/Refractory Patients | P Moreau | 3:30 PM |
| Treatment Options for Later Relapse and Refractory Patients | S Lonial | 3:45 PM |
Refreshment Break and EXHIBITionS 4:00 - 4:30 PM |
||
| Hot Topics in Myeloma | ||
| In 2019, is ASCT the right answer for all transplant eligible MM patients? | 4:30 - 5:00 PM | |
| Session Moderators | M Cavo/S Zweegman | |
| Panelists | M Mohty/H Goldschmidt/D Siegel/F Gay | |
| In 2019, when is allogeneic transplant the right answer for MM ? | 5:00 - 5:30 PM | |
| Session Moderators | S Giralt/H Einsele | |
| Panelists | J Wolf/G Gahrton/W Bensinger/A Krishan | |
| Keynote Addresses | ||
| What are the critical unanswered questions for MM in 2019? | M Dimopoulos (Introduction by N Raje) | 5:30 PM |
| Castleman’s Disease: A Personal Journey | DC Fajgenbaum (Introduction by S Treon) | 5:45 PM |
| Day Adjournment | 6:00 PM | |
Opening Ceremonies and Young Investigator Award
|
||
